Perspective Therapeutics, Inc. (CATX)
NYSEAMERICAN: CATX · Real-Time Price · USD
3.810
-0.170 (-4.27%)
At close: Aug 13, 2025, 4:00 PM
4.000
+0.190 (4.99%)
After-hours: Aug 13, 2025, 6:30 PM EDT
Perspective Therapeutics Employees
As of December 31, 2024, Perspective Therapeutics had 140 total employees, including 138 full-time and 2 part-time employees. The number of employees increased by 21 or 17.65% compared to the previous year.
Employees
140
Change (1Y)
21
Growth (1Y)
17.65%
Revenue / Employee
$8,821
Profits / Employee
-$678,236
Market Cap
282.94M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
CATX News
- 12 hours ago - Perspective Therapeutics Provides Recent Business Highlights and Reports 2Q 2025 Results - GlobeNewsWire
- 11 days ago - Perspective Therapeutics: Giving Us Some Valuable Perspective On Alpha Emitter Therapy - Seeking Alpha
- 20 days ago - Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the ESMO Congress 2025 - GlobeNewsWire
- 4 weeks ago - Perspective Therapeutics to Provide Business Highlights and Report Second Quarter 2025 Financial Results - GlobeNewsWire
- 7 weeks ago - Perspective Therapeutics Commences Recruitment for [212Pb]VMT-α-NET in the Third Dose Escalation Cohort of its Ongoing Phase 1/2a Clinical Trial - GlobeNewsWire
- 7 weeks ago - Perspective Therapeutics Presents at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2025 Annual Meeting - GlobeNewsWire
- 2 months ago - Perspective Therapeutics Highlights Updated Interim Data from its Ongoing Phase 1/2a Clinical Trial of [212Pb]VMT-α-NET at the 2025 ASCO Annual Meeting - GlobeNewsWire
- 3 months ago - Perspective Therapeutics Provides Recent Business Highlights and Reports 1Q 2025 Results - GlobeNewsWire